Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The BELIEVE-VHL Trial: A Real-world Longitudinal Study on Belzutifan's Effectiveness, Pharmacogenetics, and Pharmacoeconomics in Von Hippel-Lindau (VHL) Syndrome Using the HIF2α Inhibitor Belzutifan

NCT07167329 is registered in ClinicalTrials.gov with José Claudio Casali da Rocha as lead sponsor.

NCT NCT07167329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07167329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The BELIEVE-VHL Trial: A Real-world Longitudinal Study on Belzutifan's Effectiveness, Pharmacogenetics, and Pharmacoeconomics in Von Hippel-Lindau (VHL) Syndrome Using the HIF2α Inhibitor Belzutifan
Lead sponsor
José Claudio Casali da Rocha
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2024
Completion date
January 1, 2030
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endolymphatic sac tumor, hemangioblastoma (hb) of the central nervous system (cns), pheochromocytoma/paraganglioma, pnet, retinal angiomatous proliferation, von hippel lindau, von hippel lindau disease, von hippel lindau-deficient clear cell renal cell carcinoma